Navigation Links
T2 Bio publishes data supporting diagnostic test T2Candida in Science Translational Medicine
Date:4/25/2013

Lexington, MA, April 24, 2013 (Embargoed until 2:00 PM US Eastern Time) T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the publication of research supporting the Company's flagship diagnostic test, T2Candida, in Science Translational Medicine. The research highlights T2Candida as a breakthrough approach to rapid and sensitive identification of species-specific Candida, a sepsis-causing fungus, directly from whole blood in approximately three hours, or up to 25 times faster than the current gold standard of blood culture. This publication marks the first clinical study of patient samples with T2 Magnetic Resonance (T2MR) technology. Bloodstream infections of Candida, known as candidemia, are associated with a 40% mortality rate, largely due to the elapsed time from infection onset to pathogen diagnosis and treatment, which can take from two to five days with blood culture. With early identification of the specific species, this high mortality rate can be reduced to 11%.

"The rapid detection of Candida is of critical need within the healthcare community, where time is of the essence to enable life-saving treatment decisions," said Eleftherios Mylonakis, MD, Dean's Professor of Medicine, Chief, Infectious Disease Division, Warren Alpert Medical School of Brown University, and investigator in this study. "Studies have shown that each hour of delayed treatment increases the mortality of sepsis patients significantly, by up to 8% or more. This research outlines how T2 magnetic resonance can revolutionize the field, with great implications on mortality rates and healthcare costs."

"This research represents the first time that Candida has been identified directly from whole blood in patient samples with highly sensitive T2MR technology that affords limits of detection as low as 1 CFU/mL," added Tom Lowery, PhD, Vice President, Diagnostics Research & Development, T2 Biosystems, and principle investigator of the study. "Importantly, this T2MR approach to Candida identification is also amenable to virtually any molecular, immunoassay or hemostasis target, and we are currently developing a portfolio of products where high sensitivity and rapid detection will have the greatest impact on healthcare."

"T2MR represents a revolutionary, highly-sensitive nanotechnology solution, which can rapidly detect pathogens leading to early intervention that can save lives," said Robert S. Langer, D. Sc., David H. Koch Institute Professor, MIT, and co-founder and board member of T2 Biosystems. "T2Candida exemplifies the potential of nanotechnology to create great advances in healthcare in the near term."

In the paper entitled "T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood", the authors introduce a novel diagnostic method based on T2 magnetic resonance (T2MR). The T2Candida assay uses blood-compatible polymerase chain reaction (PCR) to amplify Candida DNA, which then binds to superparamagnetic nanoparticles coated with a complementary DNA strand. The binding event causes the nanoparticles to cluster, which changes the sample's T2MR signal. Using this approach, the researchers tested both Candida-spiked and patient samples and were able to rapidly, accurately and reproducibly detect five Candida species within human whole blood with a limit of detection as low as 1 CFU/mL and a time-to-result of approximately three hours. Spiked samples showed 98% positive agreement and 100% negative agreement between T2MR and blood culture. Clinical samples demonstrated similar concordance with blood culture with the important distinction that T2MR was able to identify Candida species in the presence of antifungals, whereas blood culture could not. This study suggests that rapid diagnosis of specific Candida species is achievable with T2MR technology, which is fully automated and applicable to a broad variety of targets.


'/>"/>

Contact: Karen Sharma
ksharma@macbiocom.com
781-235-3060
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Related biology technology :

1. T2 Bio publishes data supporting diagnostic test T2Candida® in Science Translational Medicine
2. Rigaku Publishes New Method for Elemental Analysis of Residual Oil by EDXRF
3. Exterminate Bed Bugs Like a Professional, My Cleaning Products Publishes a New Guide and Advises Use of Bed Bug Bully to Help
4. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
5. Rigaku Publishes Analysis Method for P, S and Cl in Bio-diesel and Bio-ethanol Using Primini Biofuel WDXRF
6. Rigaku Publishes EDXRF Method for Iron in Ore Materials
7. Rigaku publishes new WDXRF Application: Determination of Metals in Copper Concentrate by Advanced Correction Method for Fused Beads
8. PeerJ Publishes Its First Articles
9. New Norovirus "Vomiting Virus" Strain Spreads Like Wildfire, My Cleaning Products Publishes Green Guide to Prevent Norovirus Outbreaks in One's Home
10. Rigku Publishes New Method for Quantitative Analysis of Cast Iron Using the ZSX Primus III+
11. Rigaku Publishes method for Determination of Sulfur in Bio-gasoline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... SANTA MONICA, Calif. , March 22, 2017 ... Council (MassMEDIC) are proud to announce their extended partnership ... Week will be headlined by the 21 st ... UBM,s BIOMEDevice Boston, taking place May 3-4, 2017. ... with Advanced Medical Technology Association (ADVAMED) President and ...
(Date:3/22/2017)... 2017 MarketNewsUpdates.com News Commentary  ... The traditional ways ... pressured as of late due to the rise of the ... a dramatic impact on patient,s quality of life as Biotech ... identifying new forms of opioid formulations that prevent abuse. Biotech ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced ... of their live events series, “Stem Cell Therapy: The Next Phase in the Evolution ... 2013 Stem Cell Research and Therapy Act, Okyanos maintains a mission to ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the information you ... activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... March 2, 2017 Who risk to be ... Download the full report: https://www.reportbuyer.com/product/4313699/ WILL ... SENSOR FIELD? Fingerprint sensors using capacitive technology represent ... sensor vendor Idex forecasts an increase of 360% of ... and of the fingerprint sensor market between 2014 and ...
(Date:3/1/2017)... March 1, 2017  Aware, Inc. (NASDAQ: AWRE), a ... Richard P. Moberg has resigned, effective March ... Chief Financial Officer and Treasurer of Aware citing a ... as a member of the Board of Directors of ... co-Chief Executive Officer and co-President, General Counsel has been ...
Breaking Biology News(10 mins):